Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
Top Cited Papers
Open Access
- 19 November 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 114 (21) , 4713-4720
- https://doi.org/10.1182/blood-2009-04-217687
Abstract
An important hallmark of cancer progression is the ability of tumor cells to evade immune recognition. Understanding the relationship between neoplasKeywords
This publication has 29 references indexed in Scilit:
- Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphomaBlood, 2009
- Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximabBlood, 2009
- Eμ- TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunctionProceedings of the National Academy of Sciences, 2009
- T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapyBlood, 2009
- Regulation of macrophage function in tumors: the multifaceted role of NF-κBBlood, 2009
- Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocolsHaematologica, 2009
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cellsBlood, 2008
- Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T‐regulatory cellsInternational Journal of Cancer, 2008
- Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drugJournal of Clinical Investigation, 2008
- Tregs and rethinking cancer immunotherapyJournal of Clinical Investigation, 2007